For nearly two years, University of Michigan neurologist Eva Feldman, M.D., has led the nation’s first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig’s disease.
An amazing story of courage and determination has resulted in a new world record.
Three patients with amyotrophic lateral sclerosis will be permitted to receive a second dose of stem cells delivered directly to the spinal cord, in a clinical trial being led by the University of Michigan’s Eva Feldman, M.D.
Synthetic Biologics Inc. (NYSE Amex: SYN) Thursday announced the release of its investor relations mobile iPhone App, called the “SYN IR” App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.
Adeona Pharmaceuticals Inc. has swapped bosses as it continues testing new drugs for multiple sclerosis, fibromyalgia and Lou Gehrig’s disease. It’s also considering a new business focus and a name change.
Pharma startup Adeona and its research partner report no safety issues related to high doses of zinc to slow the effects of Lou Gehrig’s Disease
The pharma startup Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, reported its third quarter 2011 financial results Monday.
Hundreds of people across southeast Michigan are going to “Walk and Roll” for ALS on Sunday at Kensington Metropark in Milford and Stony Creek Metropark in Shelby Township.
Ann Arbor-based Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of medicines for serious central nervous system diseases, Monday reported its second quarter financial results for the period ended June 30, as well as updates since the beginning of the second quarter.
More news on clinical trials for stem cell cures for some of mankind’s most dreaded diseases emerged Tuesday from the World Stem Cell Summit in Detroit. Thomas Okarma, president and CEO of Menlo Park, Calif.-based […]